» Articles » PMID: 11124390

Effects of SR141716A, a Central Cannabinoid Receptor Antagonist, on Food-maintained Responding

Overview
Publisher Elsevier
Date 2000 Dec 22
PMID 11124390
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Previous reports have indicated that administration of the central cannabinoid receptor (CB(1)) antagonist SR141716A decreases intake of highly palatable food and drink. Disruption of normal food intake has been reported only at high doses known to disrupt spontaneous behaviors. The present study was designed to determine if rates of responding for normal food were sensitive to the effects of cannabinoid receptor blockade. Adult, male Sprague-Dawley rats were trained to lever press for normal food pellets under a fixed-ratio 15 (FR 15) schedule of reinforcement. SR141716A (0.3-3.0 mg/kg) produced dose-dependent reductions in response rate. WIN 55,212-2 (0. 3 mg/kg), a high efficacy cannabinoid agonist, given as a pre-treatment to SR141716A, significantly attenuated the rate-suppressing effects of SR141716A, suggesting a principal role of CB(1) receptors in mediating these behavioral effects. These data indicate that high palatability is not necessary to observe an anorectic effect of SR141716A.

Citing Articles

Cannabinoid type-1 receptor signaling in dopaminergic Engrailed-1 expressing neurons modulates motivation and depressive-like behavior.

Baddenhausen S, Lutz B, Hofmann C Front Mol Neurosci. 2024; 17:1379889.

PMID: 38660383 PMC: 11042029. DOI: 10.3389/fnmol.2024.1379889.


Toxic effects of AB-CHMINACA on liver and kidney and detection of its blood level in adult male mice.

Mohammad S, Mousa R, Gebril S, Mohamed Masoud K, Radwan R Forensic Toxicol. 2023; 42(1):7-17.

PMID: 37573525 PMC: 10808145. DOI: 10.1007/s11419-023-00670-0.


The conserved endocannabinoid anandamide modulates olfactory sensitivity to induce hedonic feeding in C. elegans.

Levichev A, Faumont S, Berner R, Purcell Z, White A, Chicas-Cruz K Curr Biol. 2023; 33(9):1625-1639.e4.

PMID: 37084730 PMC: 10175219. DOI: 10.1016/j.cub.2023.03.013.


Hepatic targeting of the centrally active cannabinoid 1 receptor (CBR) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes.

Hirsch S, Hinden L, Naim M, Baraghithy S, Permyakova A, Azar S J Control Release. 2022; 353:254-269.

PMID: 36442615 PMC: 9900386. DOI: 10.1016/j.jconrel.2022.11.040.


Cannabinoid receptor type 1 antagonists alter aspects of risk/reward decision making independent of toluene-mediated effects.

Braunscheidel K, Okas M, Floresco S, Woodward J Psychopharmacology (Berl). 2021; 239(5):1337-1347.

PMID: 34291308 PMC: 9885490. DOI: 10.1007/s00213-021-05914-8.